Related Experiment Video
Updated: Jul 14, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
MiR-503-5p as a potential biomarker for deep venous thrombosis (DVT) in multiple myeloma (MM) and its role in disease
Yifei Guo1, Lixiang Yan1, Xi Yang1
1Department of Hematology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, No. 88, Changling road, Xiqing District, 300380, China.
Abstract:
Given the adverse impact of deep vein thrombosis (DVT) on the prognosis of multiple myeloma (MM) patients, identifying biomarkers for DVT is crucial for improving MM patient clinical outcomes. Therefore, this study aimed to evaluate the predictive value of miR-503-5p for DVT in MM, and explored the underlying mechanisms. Serum samples were collected from MM patients with and without DVT to measure miR-503-5p expression levels. ROC and Kaplan-Meier curves were employed to examine the predictive potential of miR-503-5p in MM-related DVT. MM serum-cultured human umbilical vein endothelial cells (HUVECs) were used to investigate the mechanisms of miR-503-5p in influencing the disease. Cell viability, oxidative stress status, and IL-6, TNF-α, TF, and TM levels were evaluated by CCK-8, antioxidant activity assay, and qRT-PCR. MiR-503-5p was upregulated in MM patients with DVT. The upregulation of miR-503-5p was a risk factor that demonstrated a high predictive value for DVT in MM patients. MiR-503-5p upregulation mediated the promotive effect of MM serum on HUVEC viability reduction, IL-6, TNF-α, and TF expression, and oxidative stress, and the inhibitory effect of MM serum on HUVEC TM expression. Moreover, WNT3A was a potential target of miR-503-5p in MM-related DVT. WNT3A downregulation mediated the effect of miR-503-5p on HUVECs. MiR-503-5p might be a promising biomarker for predicting DVT development in MM patients. MiR-503-5p might promote thrombosis in MM by affecting vein endothelial cells (VECs) through targeting WNT3A.
Insights
MicroRNA-503-5p (miR-503-5p) is elevated in multiple myeloma (MM) patients with deep vein thrombosis (DVT). This microRNA may serve as a predictive biomarker for DVT in MM, potentially by targeting WNT3A and affecting vein endothelial cells.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Deep vein thrombosis (DVT) adversely affects multiple myeloma (MM) patient prognosis.
- Identifying reliable biomarkers for DVT in MM is critical for improving clinical outcomes.
Purpose of the Study:
- To evaluate the predictive value of miR-503-5p for DVT in MM patients.
- To explore the underlying mechanisms by which miR-503-5p influences DVT development in MM.
Main Methods:
- Serum samples from MM patients with and without DVT were analyzed for miR-503-5p expression.
- Receiver Operating Characteristic (ROC) and Kaplan-Meier curves were used for predictive analysis.
- In vitro studies using human umbilical vein endothelial cells (HUVECs) exposed to MM serum investigated mechanistic pathways, including cell viability, oxidative stress, and expression of IL-6, TNF-α, TF, and TM.
Main Results:
- MiR-503-5p was significantly upregulated in MM patients with DVT, showing high predictive value.
- Upregulated miR-503-5p promoted HUVEC viability reduction, increased IL-6, TNF-α, and TF expression, enhanced oxidative stress, and decreased TM expression.
- WNT3A was identified as a direct target of miR-503-5p, with its downregulation mediating miR-503-5p's effects on HUVECs.
Conclusions:
- MiR-503-5p is a potential biomarker for predicting DVT in MM patients.
- MiR-503-5p may promote thrombosis in MM by targeting WNT3A and impacting vein endothelial cells.
